CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating in the Association for Value-Based Cancer Care (AVBCC) Summit.
The 2023 AVBCC Summit features keynote speakers, interactive panel discussions, and informative sessions designed to foster collaboration, innovation and progress in the field of value-based cancer care. The industry-leading conference is scheduled to take place October 18-20 at the New York Athletic Club in New York City.
Dr. Virnich is scheduled to speak on the following topics:
TOI’s subject matter experts are also scheduled to present on panels including: Payers and Future Value-Based Transformation, Clinician Leadership Role in Transforming Cancer Care, End of Life: Have we Made Improvement to this Legacy Issue? and more.
For more information about the 2023 AVBCC Summit, including registration details and the full agenda, please visit valuebasedcancer.com/avbcc/2023-summit.
About TOI
Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 800 teammates in over 65 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.77 |
| Daily Change: | -0.01 -0.26 |
| Daily Volume: | 1,092,379 |
| Market Cap: | US$370.890M |
November 13, 2025 November 13, 2025 September 29, 2025 September 02, 2025 August 18, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
